Amicus Therapeutics
Manufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
47 Hulfish St, Princeton, New Jersey, 08...Phone Number
(609) 662-2000Website
www.amicusrx.comRevenue
$634.2 MillionStock Symbol
FOLDIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
6
1
2
1
2
About Amicus Therapeutics
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.Explore more
Amicus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amicus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Amicus Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Amicus Therapeutics is spiking on competitors!
Product Launch: Get notified when Amicus Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Amicus Therapeutics
Funding: Get notified immidiatlly once Amicus Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Amicus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Amicus Therapeutics had a recent Job posting/layoffs
Check if Amicus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Amicus Therapeutics
Find 2 more new buyers
Compare Similar Companies to Amicus Therapeutics
Compare insights from companies similar to Amicus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$673M
1K - 5K
Public
$1.6B
2010
AM
Alyssa MooreChief of Staff and Head Senior Vice President, Program and Portfolio Management
Company Profile Activity
Activity Insights
Amicus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amicus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amicus Therapeutics.
Amicus Therapeutics financials insights
Gather financial insights about Amicus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$75M
2020
Debt
$400M
Amicus Therapeutics Tech Stack
A closer look at the technologies used by Amicus Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Layoffs, Acquisitions
Person-Based
Layoffs, Acquisitions
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Amicus Therapeutics News & Media
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026 SAN...CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CERTD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amicus Therapeutics
Sign Up For FreeTo access detailed company insights
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.... Read More
